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Abstract 
 
Background: 
Management of screen-detected ductal carcinoma in situ (DCIS) remains controversial.  
Methods: 
A prospective cohort of DCIS diagnosed through the UK National Health Service Breast Screening 
Programme (1 April 2003 to 31 March 2012) was linked to national databases and case note 
review to analyse patterns of care, recurrence and mortality.  
Results:  
Screen-detected DCIS in 9938 women, mean age 60 years (range 46-87), was treated by 
mastectomy (2931) or breast conservation surgery (BCS) (7007; 70%). At 64 months median follow 
up, 697 (6.8%) had further DCIS or invasive breast cancer after BCS (7.8%) or mastectomy (4.5%) 
(p<0.001). Breast radiotherapy (RT) after BCS (4363/7007; 62.3%) was associated with a 3.1% 
absolute reduction in ipsilateral recurrent DCIS or invasive breast cancer (No RT: 7.2% vs RT: 4.1% 
(p<0.001) and a 1.9% absolute reduction for ipsilateral invasive breast recurrence (No RT: 3.8% vs 
RT: 1.9% (p<0.001), independent of excision margin width or size of DCIS. Women without RT after 
BCS had more ipsilateral breast recurrences (p<0.001) when the radial excision margin was <2mm. 
Adjuvant endocrine therapy (1208/9938; 12%) was associated with a reduction in any ipsilateral 
recurrence, whether RT was received (HR 0.57: 95% CI 0.41 - 0.80) or not (HR 0.68: 95% CI 0.51 - 
0.91) after BCS. Women who developed invasive breast recurrence had a worse survival than 
those with recurrent DCIS (p<0.001). Among 321 (3.2%) who died, only 46 deaths were attributed 
to invasive breast cancer.  
Conclusion: 
Recurrent DCIS or invasive cancer is uncommon following screen-detected DCIS. Both RT and 
endocrine therapy were associated with a reduction in further events but not with breast cancer 
mortality within 5 years of diagnosis. Further research to identify biomarkers of recurrence risk, 
particularly as invasive disease, is indicated. 
 
Keywords: Ductal carcinoma in situ (DCIS); radiotherapy; margins; recurrence. 
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Introduction 
 
Ductal carcinoma in situ (DCIS) comprises 20-25% of screen-detected breast cancer and, like 
invasive breast cancer, is heterogeneous in terms of underlying biology, presentation and 
outcome [1]. The clinical behaviour of DCIS is unpredictable, challenging clinical decision-making. 
Recently, concern regarding the over-treatment of DCIS [1], has been fueled by large retrospective 
American series demonstrating excellent (>95%) long term survival 10-20 years after diagnosis 
although others have suggested that detection and treatment of screen-detected DCIS may 
prevent subsequent invasive disease. [2-4]  
Standard treatment for DCIS includes mastectomy or breast conserving surgery (BCS), with or 
without radiotherapy (RT) and/or endocrine therapy to decrease ipsilateral recurrence and/or 
contralateral breast carcinoma. [5-7] It remains unclear which patients benefit from these 
adjuvant therapies. Prospective data are lacking and the clinical significance of early detection and 
treatment for DCIS remains unclear. Here, we report the first analysis of recurrence and mortality 
from a prospective cohort study of DCIS detected through a contemporary national screening 
programme. Utilising diagnostic imaging, surgery, histopathology and adjuvant therapy data 
provided by the local breast screening unit where diagnosis was reached, along with longitudinal 
follow-up of patients through case note review and linkage to national databases, we describe the 
features and outcomes following diagnosis of screen-detected DCIS.  
 
Methods 
The United Kingdom National Health Service Breast Screening Programme (NHSBSP) invites 
women aged 50-70 to attend breast screening every three years (supplementary figure and text 
p2). The Sloane Project was established in memory of Professor John Sloane, a breast pathologist, 
to audit the features, patterns of care and outcomes for women with non-invasive neoplasia 
detected within the NHSBSP. Data capture was via radiology, pathology, surgery and radiotherapy 
(RT) paper proformas collected at screening unit level, sent to Public Health England, then each 
patient’s data entered on a secure database held on an SQL server that generated an individual 
patient and tumour identifier. The data reported here is for women in the dataset who had DCIS 
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identified. For the 34 women with bilateral DCIS, the higher grade and/or larger lesion was 
considered the index.  
 
Data included demographic, diagnostic, treatment and vital status. Adherence to NHSBSP 
guidelines and participation in the relevant quality assurance programmes were mandatory. 
Participating units were required to follow a pathology protocol containing definitions for DCIS, 
microinvasion, cytonuclear grade, comedo necrosis and assessment of excision margins and to 
handle and report specimens to NHSBSP pathology standards. [8] Radiology guidelines mandated 
participating radiologists should complete detailed radiology proformas [9] and participate in the 
NHSBSP PERFORMS external quality assurance scheme. [10] 
 
Missing (unknown) data were rare for key comparisons including use of radiotherapy (0.5%), grade 
of DCIS (0.1%), lesion size (0.4%) or cause of death (0.1%). Events were identified by matching 
women by NHS number and date of birth to information provided by breast screening units, and 
to routinely collected UK datasets including Hospital Episode Statistics (HES), Cancer Waiting Times 
(CWT), the English Cancer Analysis System (CAS)/National Cancer Registration and Analysis Service 
(NCRAS), the English National Radiotherapy Dataset (RTDS) and the Information Services Division, 
Scotland (ISD). The census date was the date of death or 31 December 2012. Validation of data 
was undertaken by cross-checking with original screening unit source documents for those 
patients with recurrence and more generally, for the overall dataset, against the Association of 
Breast Surgery national audits 2006-2012. 
 
Ethics Committee approval was not required for this prospective cohort study originally conducted 
under the NHS Cancer Screening Programme's application to the Patient Information Advisory 
Group (PIAG). More recently, access to patient data was approved to quality assure National 
Cancer Screening Programmes under the Health and Social Care Act 2006 (Section 251) via the 
Confidentiality Advisory Group (CAG).  
 
Classification of recurrence & mortality 
Given the difficulties in distinguishing local recurrence versus a new primary lesion in the same 
breast, the following terminology was used (see supplementary figure and text p 2-3). A ‘breast 
event’ was defined as (any of): ipsilateral breast recurrence (or new primary) after BCS; ipsilateral 
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recurrence (includes post-mastectomy/chest wall recurrence); regional or distant recurrence; or 
contralateral re/occurrence. (See supplementary figure and text, [p3-4] for definitions of 
mortality). 
 
Statistical analyses 
Logistic linear regression analysis was used to test the relationship between a binary variable and 
continuous or ordered categorical dependent variables. The importance of factors was determined 
by likelihood ratio tests that compared the full model and a reduced model with one factor 
removed at a time. A factor with a lower p-value from the likelihood ratio test was deemed to be 
more important than one with a higher p-value. 
 
For disease recurrence, cumulative incidence plots were produced, taking account of the 
competing risks between recurrence and death. K-sample tests were performed to compare the 
groups in the cumulative incidence plots. For overall and breast cancer specific survival, Kaplan-
Meier survival plots were produced; log rank tests were used to test the difference between 
survival curves. All time to event analyses were performed using the Cox semi-parametric 
proportional hazard regression. Tied times were adjusted using the Breslow’s method. The 
proportional hazard assumption was assessed by Schoenfeld residuals test. For most analyses, the 
proportional hazard assumption is valid. Analyses were performed in R. Considering the high 
number of variables and groups within the variables, probability values lower than one in a 
hundred (0.01) were used to assign statistical significance. 
 
Results 
 
Patterns of care 
From 12,788 patients (12,838 non-invasive lesions) diagnosed from 1 April 2003 to 31 March 2012 
complete data were available for 9938 women (age range 46-87, mean age 60) diagnosed with 
DCIS (with or without lobular carcinoma in situ (LCIS) and/or atypical ductal hyperplasia (ADH)) 
(Figure 1). Seventy-eight breast screening units in England and Scotland contributed data (82% of 
the 95 units). Median follow up was 64 months (range 6 - 116 months). Over the same decade in 
the UK, 30,187 women were diagnosed with non-invasive and microinvasive breast cancers 
through the NHSBSP; thus, the data analysed represent 77% (9938/12,838) of non-invasive lesions 
Page 7 
 
 
within this prospective cohort, and 33% (9938/30,187) of women with a final diagnosis of in situ 
breast carcinoma diagnosed through the NHSBSP.  
 
Surgical treatment 
Breast conservation surgery (BCS) was definitive surgery in 7007 (70%) women and was utilised 
more often with increasing age up to 59 years and thereafter appeared constant. Mastectomy was 
definitive surgery for 2931 (30%) women. The use of mastectomy was associated with DCIS of high 
or intermediate rather than low grade (p<0.001) and with larger lesion size (p<0.001). The use of 
BCS versus mastectomy was unchanged over time.  
 
Radiotherapy 
For 7007 women who had BCS, 62% also had RT; the use of RT increased over time (p<0.001). 
Women aged 70 or older were less likely to have RT compared to women aged 50-70 (p=0.006). 
Use of RT after BCS increased with grade of DCIS (p<0.001), DCIS size (p<0.001), the presence of 
microinvasion (p<0.001) and comedo necrosis (p<0.001), but not with margin width (Table 1), 
confirmed by multivariable analysis (result not shown). RT was administered after mastectomy in 
33 (1%) women, as previously reported. [11] 
 
Endocrine Therapy 
Endocrine therapy was prescribed to more women following BCS (14%) than mastectomy (8%) 
(p<0.001). The use of endocrine therapy was not related to age and was prescribed less frequently 
over time (p<0.001). There was no relationship between the receipt of endocrine therapy and RT 
use after BCS. 
 
Outcomes 
At a median follow up of 64 months, 6.8% of women (679/9938) had a breast (DCIS or invasive) 
event: 451 (4.5%) were ipsilateral breast, regional or distant recurrences and 228 (2.3%) 
represented a re/occurrence in the contralateral breast/nodes. Ipsilateral breast recurrence after 
BCS was 5.3% (368/7007); ipsilateral chest wall recurrence after mastectomy was 0.8% (24/2931). 
The risk of a further breast event did not differ by year of screening. 
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Recurrence following BCS 
Following BCS, there was a greater risk of ipsilateral breast recurrence for those who did not have 
RT compared to those who had RT (p<0.001, HR=0.59: 95% CI0.53 - 0.67) (no RT: 7.2% vs RT: 4.1%) 
(Figure 2). There was a significantly lower risk of invasive ipsilateral breast recurrence (no RT: 3.8% 
vs RT: 1.9%) (p<0.001, HR=0.51: 95% CI 0.43 - 0.60) but not ipsilateral DCIS recurrence (no RT: 
3.3% vs RT: 2.2%) (p=0.05, HR=0.69: 95% CI =0.58 - 0.82.) in women who received RT.  
 
After BCS, the risk of developing ipsilateral breast recurrence was greater in patients with a 
negative or close DCIS margin (0 to <2mm: 7.4% vs ≥2mm: 4.8%; p<0.001, HR=0.67: 95% CI 0.57 - 
0.78), (p <0.001) whether patients received RT (p=0.011, HR=0.75: 95% CI 0.60 - 0.94) or not 
(p<0.001, HR=0.59: 95% CI 0.47 - 0.73).  
 
RT and endocrine therapy were independently associated with a decreased risk of ipsilateral 
breast recurrence (RT: p<0.001, HR=0.59: 95% CI 0.52 – 0.66; endocrine therapy; p=0.003, HR=0.7: 
95% CI 0.55 – 0.89; interaction: p=0.20).  
 
Multivariable analyses for recurrence 
By multivariable analyses, following BCS, use of RT (HR 0.38: 95% CI 0.33-0.45) and endocrine 
therapy (HR 0.63: 95% CI 0.50 - 0.78) were each independently associated with a significantly 
reduced risk of breast events and ipsilateral breast recurrence (RT: HR 0.40: 95% CI 0.34 - 0. 48) 
(endocrine therapy: HR 0.56: 95% CI 0.44 - 0.72).  
 
After adjusting for all other factors, the presence of high grade of DCIS and of comedo necrosis 
were significantly associated with a higher risk of breast events (excluding contralateral 
occurrence) (high grade - HR 1.50: 95% CI 1.14 - 1.98, comedo necrosis HR 1.31: 95% CI 1.09 - 1.57) 
and of ipsilateral breast recurrence (high grade - HR 1.40: 95% CI 1.05 - 1.87); comedo necrosis - 
HR 1.30: (95% CI 1.07 – 1.57).  
 
Contralateral disease 
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Contralateral breast cancer was seen in 218 women (2.2%);more commonly after mastectomy 
(81/2931; 2.8%) than after BCS (137/7007; 1.9%) (p<0.001). 
 
Survival  
Among the 9938 women, there were 321 deaths (3.2%), 46  attributed to breast cancer. There was 
no difference in overall (or breast cancer-related) mortality comparing BCS (3.1% [218/7007]) to 
mastectomy (3.5% [103/2931]).  
 
Women treated with RT after BCS had a lower all-cause mortality (RT: 2.5% vs no RT: 4.2%; 
p<0.001), even when corrected for age (p<0.001, HR=0.65: 95% CI 0.49 - 0.85), but not a lower 
breast cancer mortality (p=0.41, HR=0.73: 95% CI 0.34 - 1.56) The use of endocrine therapy was 
not associated with overall or breast cancer specific mortality.  
 
Women who developed an invasive breast recurrence had a significantly worse overall survival 
(log rank p-value <0.001) and breast cancer specific survival (log rank p-value<0.001) from the 
time of the further event compared with those who developed recurrent DCIS (Figure 3) 
(supplementary figure 1).  
 
Discussion 
This study of 9938 women with DCIS detected through the UK NHSBSP confirms that recurrent 
DCIS or invasive cancer remains a concern following modern management of screen-detected 
DCIS. Both RT and endocrine therapy were associated with a reduction in further events but not 
with breast cancer mortality within 5 years of diagnosis. The present prospective cohort study 
contrasts with recent but retrospective studies of US [2, 3] and European data. [12] Unlike those 
series, we report prospectively collected data from the setting of an established national breast 
screening programme, with built in quality assurance of imaging, surgery, pathology and RT. [10, 
13] An additional major strength, in contrast to other studies including the randomised clinical 
trials, is the prospective collection of margin status, an area of significant international 
controversy. In addition, available data include the use of endocrine therapy with linkage to 
outcomes. [2, 3] Conversely, one limitation of the present study, in keeping with the recently 
published retrospective series [2-4, 12] is its observational nature with the consequent difficulty in 
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accounting for all possible confounders. Follow up is also relatively short in the context of the long 
natural history of DCIS. 
 
Breast conservation was the definitive surgery for 70.5% of women, more frequently used with 
increasing age. This may reflect perceptions about risk of within breast recurrence in younger 
patients. Whilst it is likely that RT following BCS was used in patients perceived (based on 
pathological and patient-related factors) to be at higher risk of recurrence, RT use was, 
surprisingly, not associated with close or involved circumferential resection margins. Conversely, 
mastectomy was, not unexpectedly, associated with features of more aggressive DCIS.  
 
RT following BCS was associated with a significant reduction in all ipsilateral breast further events 
(DCIS or invasive) at a median follow up of 64 months. The association of RT with reduced 
recurrence risk is consistent with the effects seen in the overview of the prospective randomized 
trials. [14] Significantly, however, in the present study, the reduction of breast recurrence 
associated with RT was independent of margin of excision. Differing minimum margin widths for 
DCIS have been proposed [15, 16]. One recent series has suggested that a 1mm margin may be 
sufficient, with or without RT [17]. Others have suggested that those with margin widths <1mm 
may benefit from postoperative radiation therapy whilst those with >10mm margins receive no 
benefit with regard to recurrence. [18] However, specifically for women who did not receive RT, in 
this series there was an association between a DCIS margin of <2mm and ipsilateral breast 
recurrence. This provides direct evidence in support of more recent reviews, meta-analysis and 
consensus guidelines [19, 20] as well as recent studies [21]. 
 
 
The higher all-cause mortality in patients not receiving RT after BCS is likely to reflect 
comorbidities not captured in the current study. Nevertheless, patients not receiving RT had a 
higher (7.2%) breast recurrence rate, confirming patient selection for RT could be improved. [22] 
Endocrine therapy was associated with a non-significant reduction in ipsilateral breast recurrence 
independent of RT, although the greatest effect was seen for the reduction of invasive further 
events in the absence of RT. In a contemporary analysis of the US retrospective National Cancer 
Data Base (70% of the US population), 36.5% of women (most commonly between 50 and 59 years 
of age) received adjuvant endocrine therapy for DCIS [23] compared with 12.2% in this UK-based 
study, and no-one in a cohort in the Netherlands [12], reflecting the inconsistent interpretation of 
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evidence from trials examining the impact of endocrine therapy for DCIS on local recurrence, the 
associated toxicities and issues of adherence to adjuvant tamoxifen treatment. 
 
Significantly, neither the use of RT, endocrine therapy, nor type of surgery, appeared to influence 
breast cancer mortality, although women who developed invasive ipsilateral breast cancer had a 
poorer survival than those who had DCIS recurrence. Indeed, breast cancer mortality (0.46%) was 
a fifth of other cause mortality, in keeping with several retrospective studies. [2. 3, 12] 
 
The increasing incidence of DCIS, likely to be sustained with the enhanced visualisation that digital 
mammography provides, now deployed in the UK NHS BSP, emphasises the potential for 
overtreatment of women diagnosed though breast screening. [1] Since digital mammography was 
not deployed during the time of data collection for this study, the impact of digital mammography 
and any influences on the data reported here remain uncertain. However, the present study 
findings do re-emphasise the issue of potential overtreatment of DCIS and the need to improve 
the selection of adjuvant therapy for women with DCIS. This requires a greater understanding of 
the underlying biology of DCIS, on reliable predictive and prognostic assessment, particularly to 
select women at risk of invasive breast cancer recurrence. Predictive models of ipsilateral breast 
recurrence after DCIS, and a more recent prognostic score for DCIS for RT benefit, require 
prospective validation if they are to be widely adopted. [24-28] Meanwhile, a major international 
initiative between the UK, Netherlands and the US, the PRECISION (PREvent ductal Carcinoma In 
Situ Invasive Overtreatment Now) study funded by Cancer Research UK and the Dutch Cancer 
Society seeks to define underlying molecular mechanisms in DCIS related to risk of progression 
and, together with diagnostic and clinical elements, construct risk models for the future 
management of patients. (http://www.cancerresearchuk.org/funding-for-researchers/how-we-
deliver-research/grand-challenge-award/funded-teams-wesseling) [28] Emulating studies in 
prostate, thyroid and renal neoplasia, active surveillance, rather than initial surgery, for carefully 
selected patients with low risk DCIS has been advocated and may avoid the potential sequelae of 
breast surgery. Indeed, prospective randomised trials of active surveillance versus conventional 
surgical care, e.g. the LOw RISk DCIS (LORIS) trial in the UK, COMET in the USA and LORD in 
mainland Europe [29-31] seek to identify a cohort of patients with sufficiently low risk to obviate 
the need for surgical excision. 
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Conclusions 
This large prospective cohort study allows us to examine, in contemporary practice, the effects of 
present-day treatments, and the patient and pathological features that have previously been 
described in retrospective studies and randomised clinical trials. The reduction in recurrence rates 
seen with the use of RT and endocrine therapy has not, to date, yielded a survival benefit to 
patients, although other-cause mortality is five times greater than that attributable to breast 
cancer. Ipsilateral breast recurrence risk is, however, higher in patients treated by BCS without RT, 
particularly if the radial excision margin is narrow (<2mm). Women with recurrence as invasive 
disease have poorer survival than those with recurrent DCIS and further research targeting clinical, 
biological and imaging biomarkers of risk of invasive recurrence after a diagnosis of screen-
detected DCIS is indicated, to improve personalisation of therapy and outcomes. 
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Abstract 
 
Background: 
Management of screen-detected ductal carcinoma in situ (DCIS) remains controversial.  
Methods: 
A prospective cohort of DCIS diagnosed through the UK National Health Service Breast Screening 
Programme (1 April 2003 to 31 March 2012) was linked to national databases and case note review 
to analyse patterns of care, recurrence and mortality.  
Results:  
Screen-detected DCIS in 9938 women, mean age 60 years (range 46-87), was treated by mastectomy 
(2931) or breast conservation surgery (BCS) (7007; 70%). At 64 months median follow up, 697 (6.8%) 
had further DCIS or invasive breast cancer after BCS (7.8%) or mastectomy (4.5%) (p<0.001). Breast 
radiotherapy (RT) after BCS (4363/7007; 62.3%) was associated with a 3.1% absolute reduction in 
ipsilateral recurrent DCIS or invasive breast cancer (No RT: 7.2% vs RT: 4.1% (p<0.001) and a 1.9% 
absolute reduction for ipsilateral invasive breast recurrence (No RT: 3.8% vs RT: 1.9% (p<0.001), 
independent of excision margin width or size of DCIS. Women without RT after BCS had more 
ipsilateral breast recurrences (p<0.001) when the radial excision margin was <2mm. Adjuvant 
endocrine therapy (1208/9938; 12%) was associated with a reduction in any ipsilateral recurrence, 
whether RT was received (HR 0.57: 95% CI 0.41 - 0.80) or not (HR 0.68: 95% CI 0.51 - 0.91) after BCS. 
Women who developed invasive breast recurrence had a worse survival than those with recurrent 
DCIS (p<0.001). Among 321 (3.2%) who died, only 46 deaths were attributed to invasive breast 
cancer.  
Conclusion: 
Recurrent DCIS or invasive cancer is uncommon following screen-detected DCIS. Both RT and 
endocrine therapy were associated with a reduction in further events but not with breast cancer 
mortality within 5 years of diagnosis. Further research to identify biomarkers of recurrence risk, 
particularly as invasive disease, is indicated. 
 
Keywords: Ductal carcinoma in situ (DCIS); radiotherapy; margins; recurrence. 
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Introduction 
 
Although described over 80 years ago [1] ductal carcinoma in situ (DCIS) became a common 
management problem after the introduction of breast screening and now comprises 20-25% of 
screen-detected breast cancer.  Like invasive breast cancer, DCIS is heterogeneous in terms of 
underlying biology, presentation and outcome [2]. The clinical behaviour of DCIS is unpredictable, 
challenging clinical decision-making. Recently, concern regarding the over-treatment of DCIS [2], has 
been fueled by large retrospective American series demonstrating excellent (>95%) long term survival 
10-20 years after diagnosis although others have suggested that detection and treatment of screen-
detected DCIS may prevent subsequent invasive disease. [3-5]  
Standard treatment for DCIS includes mastectomy or breast conserving surgery (BCS), with or without 
radiotherapy (RT) and/or endocrine therapy to decrease ipsilateral recurrence and/or contralateral 
breast carcinoma. [6-8] It remains unclear which patients benefit from these adjuvant therapies. 
Prospective data are lacking and the clinical significance of early detection and treatment for DCIS 
remains unclear. Here, we report the first analysis of recurrence and mortality from a prospective 
cohort study of DCIS detected through a contemporary national screening programme. Utilising 
diagnostic imaging, surgery, histopathology and adjuvant therapy data provided by the local breast 
screening unit where diagnosis was reached, along with longitudinal follow-up of patients through 
case note review and linkage to national databases, we describe the features and outcomes following 
diagnosis of screen-detected DCIS.  
 
Methods 
The United Kingdom National Health Service Breast Screening Programme (NHSBSP) invites women 
aged 50-70 to attend breast screening every three years (supplementary figure and text p2). The 
Sloane Project was established in memory of Professor John Sloane, a breast pathologist, to audit the 
features, patterns of care and outcomes for women with non-invasive neoplasia detected within the 
NHSBSP. Data capture was via radiology, pathology, surgery and radiotherapy (RT) paper proformas 
collected at screening unit level, sent to Public Health England, then each patient’s data entered on a 
secure database held on an SQL server that generated an individual patient and tumour identifier. 
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The data reported here is for women in the dataset who had DCIS identified. For the 34 women with 
bilateral DCIS, the higher grade and/or larger lesion was considered the index.  
 
Data included demographic, diagnostic, treatment and vital status. Adherence to NHSBSP guidelines 
and participation in the relevant quality assurance programmes were mandatory. Participating units 
were required to follow a pathology protocol containing definitions for DCIS, microinvasion, 
cytonuclear grade, comedo necrosis and assessment of excision margins and to handle and report 
specimens to NHSBSP pathology standards. [9] Radiology guidelines mandated participating 
radiologists should complete detailed radiology proformas [10] and participate in the NHSBSP 
PERFORMS external quality assurance scheme. [11] 
 
Missing (unknown) data were rare for key comparisons including use of radiotherapy (0.5%), grade of 
DCIS (0.1%), lesion size (0.4%) or cause of death (0.1%). Events were identified by matching women 
by NHS number and date of birth to information provided by breast screening units, and to routinely 
collected UK datasets including Hospital Episode Statistics (HES), Cancer Waiting Times (CWT), the 
English Cancer Analysis System (CAS)/National Cancer Registration and Analysis Service (NCRAS), the 
English National Radiotherapy Dataset (RTDS) and the Information Services Division, Scotland (ISD). 
The census date was the date of death or 31 December 2012. Validation of data was undertaken by 
cross-checking with original screening unit source documents for those patients with recurrence and 
more generally, for the overall dataset, against the Association of Breast Surgery national audits 
2006-2012. 
 
Ethics Committee approval was not required for this prospective cohort study originally conducted 
under the NHS Cancer Screening Programme's application to the Patient Information Advisory Group 
(PIAG). More recently, access to patient data was approved to quality assure National Cancer 
Screening Programmes under the Health and Social Care Act 2006 (Section 251) via the 
Confidentiality Advisory Group (CAG).  
 
Classification of recurrence & mortality 
Given the difficulties in distinguishing local recurrence versus a new primary lesion in the same 
breast, the following terminology was used (see supplementary figure and text p 2-3). A ‘breast 
event’ was defined as (any of): ipsilateral breast recurrence (or new primary) after BCS; ipsilateral 
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recurrence (includes post-mastectomy/chest wall recurrence); regional or distant recurrence; or 
contralateral re/occurrence. (See supplementary figure and text, [p3-4] for definitions of mortality). 
 
Statistical analyses 
Logistic linear regression analysis was used to test the relationship between a binary variable and 
continuous or ordered categorical dependent variables. The importance of factors was determined 
by likelihood ratio tests that compared the full model and a reduced model with one factor removed 
at a time. A factor with a lower p-value from the likelihood ratio test was deemed to be more 
important than one with a higher p-value. 
 
For disease recurrence, cumulative incidence plots were produced, taking account of the competing 
risks between recurrence and death. K-sample tests were performed to compare the groups in the 
cumulative incidence plots. For overall and breast cancer specific survival, Kaplan-Meier survival plots 
were produced; log rank tests were used to test the difference between survival curves. All time to 
event analyses were performed using the Cox semi-parametric proportional hazard regression. Tied 
times were adjusted using the Breslow’s method. The proportional hazard assumption was assessed 
by Schoenfeld residuals test. For most analyses, the proportional hazard assumption is valid. Analyses 
were performed in R. Considering the high number of variables and groups within the variables, 
probability values lower than one in a hundred (0.01) were used to assign statistical significance. 
 
Results 
 
Patterns of care 
From 12,788 patients (12,838 non-invasive lesions) diagnosed from 1 April 2003 to 31 March 2012 
complete data were available for 9938 women (age range 46-87, mean age 60) diagnosed with DCIS 
(with or without lobular carcinoma in situ (LCIS) and/or atypical ductal hyperplasia (ADH)) (Figure 1). 
Seventy-eight breast screening units in England and Scotland contributed data (82% of the 95 units). 
Median follow up was 64 months (range 6 - 116 months). Over the same decade in the UK, 30,187 
women were diagnosed with non-invasive and microinvasive breast cancers through the NHSBSP; 
thus, the data analysed represent 77% (9938/12,838) of non-invasive lesions within this prospective 
cohort, and 33% (9938/30,187) of women with a final diagnosis of in situ breast carcinoma diagnosed 
through the NHSBSP.  
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Surgical treatment 
Breast conservation surgery (BCS) was definitive surgery in 7007 (70%) women and was utilised more 
often with increasing age up to 59 years and thereafter appeared constant. Mastectomy was 
definitive surgery for 2931 (30%) women. The use of mastectomy was associated with DCIS of high or 
intermediate rather than low grade (p<0.001) and with larger lesion size (p<0.001). The use of BCS 
versus mastectomy was unchanged over time.  
 
Radiotherapy 
For 7007 women who had BCS, 62% also had RT; the use of RT increased over time (p<0.001). 
Women aged 70 or older were less likely to have RT compared to women aged 50-70 (p=0.006). Use 
of RT after BCS increased with grade of DCIS (p<0.001), DCIS size (p<0.001), the presence of 
microinvasion (p<0.001) and comedo necrosis (p<0.001), but not with margin width (Table 1), 
confirmed by multivariable analysis (result not shown). RT was administered after mastectomy in 33 
(1%) women, as previously reported. [12] 
 
Endocrine Therapy 
Endocrine therapy was prescribed to more women following BCS (14%) than mastectomy (8%) 
(p<0.001). The use of endocrine therapy was not related to age and was prescribed less frequently 
over time (p<0.001). There was no relationship between the receipt of endocrine therapy and RT use 
after BCS. 
 
Outcomes 
At a median follow up of 64 months, 6.8% of women (679/9938) had a breast (DCIS or invasive) 
event: 451 (4.5%) were ipsilateral breast, regional or distant recurrences and 228 (2.3%) represented 
a re/occurrence in the contralateral breast/nodes. Ipsilateral breast recurrence after BCS was 5.3% 
(368/7007); ipsilateral chest wall recurrence after mastectomy was 0.8% (24/2931). The risk of a 
further breast event did not differ by year of screening. 
 
Recurrence following BCS 
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Following BCS, there was a greater risk of ipsilateral breast recurrence for those who did not have RT 
compared to those who had RT (p<0.001, HR=0.59: 95% CI0.53 - 0.67) (no RT: 7.2% vs RT: 4.1%) 
(Figure 2). There was a significantly lower risk of invasive ipsilateral breast recurrence (no RT: 3.8% vs 
RT: 1.9%) (p<0.001, HR=0.51: 95% CI 0.43 - 0.60) but not ipsilateral DCIS recurrence (no RT: 3.3% vs 
RT: 2.2%) (p=0.05, HR=0.69: 95% CI =0.58 - 0.82.) in women who received RT.  
 
After BCS, the risk of developing ipsilateral breast recurrence was greater in patients with a negative 
or close DCIS margin (0 to <2mm: 7.4% vs ≥2mm: 4.8%; p<0.001, HR=0.67: 95% CI 0.57 - 0.78), (p 
<0.001) whether patients received RT (p=0.011, HR=0.75: 95% CI 0.60 - 0.94) or not (p<0.001, 
HR=0.59: 95% CI 0.47 - 0.73).  
 
RT and endocrine therapy were independently associated with a decreased risk of ipsilateral breast 
recurrence (RT: p<0.001, HR=0.59: 95% CI 0.52 – 0.66; endocrine therapy; p=0.003, HR=0.7: 95% CI 
0.55 – 0.89; interaction: p=0.20).  
 
Multivariable analyses for recurrence 
By multivariable analyses, following BCS, use of RT (HR 0.38: 95% CI 0.33-0.45) and endocrine therapy 
(HR 0.63: 95% CI 0.50 - 0.78) were each independently associated with a significantly reduced risk of 
breast events and ipsilateral breast recurrence (RT: HR 0.40: 95% CI 0.34 - 0. 48) (endocrine therapy: 
HR 0.56: 95% CI 0.44 - 0.72).  
 
After adjusting for all other factors, the presence of high grade of DCIS and of comedo necrosis were 
significantly associated with a higher risk of breast events (excluding contralateral occurrence) (high 
grade - HR 1.50: 95% CI 1.14 - 1.98, comedo necrosis HR 1.31: 95% CI 1.09 - 1.57) and of ipsilateral 
breast recurrence (high grade - HR 1.40: 95% CI 1.05 - 1.87); comedo necrosis - HR 1.30: (95% CI 1.07 
– 1.57).  
 
Contralateral disease 
Contralateral breast cancer was seen in 218 women (2.2%);more commonly after mastectomy 
(81/2931; 2.8%) than after BCS (137/7007; 1.9%) (p<0.001). 
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Survival  
Among the 9938 women, there were 321 deaths (3.2%), 46  attributed to breast cancer. There was 
no difference in overall (or breast cancer-related) mortality comparing BCS (3.1% [218/7007]) to 
mastectomy (3.5% [103/2931]).  
 
Women treated with RT after BCS had a lower all-cause mortality (RT: 2.5% vs no RT: 4.2%; p<0.001), 
even when corrected for age (p<0.001, HR=0.65: 95% CI 0.49 - 0.85), but not a lower breast cancer 
mortality (p=0.41, HR=0.73: 95% CI 0.34 - 1.56) The use of endocrine therapy was not associated with 
overall or breast cancer specific mortality.  
 
Women who developed an invasive breast recurrence had a significantly worse overall survival (log 
rank p-value <0.001) and breast cancer specific survival (log rank p-value<0.001) from the time of the 
further event compared with those who developed recurrent DCIS (Figure 3) (supplementary figure 
1).  
 
Discussion 
This study of 9938 women with DCIS detected through the UK NHSBSP confirms that recurrent DCIS 
or invasive cancer remains a concern following modern management of screen-detected DCIS. Both 
RT and endocrine therapy were associated with a reduction in further events but not with breast 
cancer mortality within 5 years of diagnosis. The present prospective cohort study contrasts with 
recent but retrospective studies of US [3, 4] and European data. [13] Unlike those series, we report 
prospectively collected data from the setting of an established national breast screening programme, 
with built in quality assurance of imaging, surgery, pathology and RT. [11, 14] An additional major 
strength, in contrast to other studies including the randomised clinical trials, is the prospective 
collection of margin status, an area of significant international controversy. In addition, available data 
include the use of endocrine therapy with linkage to outcomes. [3, 4] Conversely, one limitation of 
the present study, in keeping with the recently published retrospective series [3-5, 13] is its 
observational nature with the consequent difficulty in accounting for all possible confounders. Follow 
up is also relatively short in the context of the long natural history of DCIS. 
 
Breast conservation was the definitive surgery for 70.5% of women, more frequently used with 
increasing age. This may reflect perceptions about risk of within breast recurrence in younger 
patients. Whilst it is likely that RT following BCS was used in patients perceived (based on 
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pathological and patient-related factors) to be at higher risk of recurrence, RT use was, surprisingly, 
not associated with close or involved circumferential resection margins. Conversely, mastectomy 
was, not unexpectedly, associated with features of more aggressive DCIS.  
 
RT following BCS was associated with a significant reduction in all ipsilateral breast further events 
(DCIS or invasive) at a median follow up of 64 months. The association of RT with reduced recurrence 
risk is consistent with the effects seen in the overview of the prospective randomized trials. [15] 
Significantly, however, in the present study, the reduction of breast recurrence associated with RT 
was independent of margin of excision. Differing minimum margin widths for DCIS have been 
proposed [16, 17]. One recent series has suggested that a 1mm margin may be sufficient, with or 
without RT [18]. Others have suggested that those with margin widths <1mm may benefit from 
postoperative radiation therapy whilst those with >10mm margins receive no benefit with regard to 
recurrence. [19] However, specifically for women who did not receive RT, in this series there was an 
association between a DCIS margin of <2mm and ipsilateral breast recurrence. This provides direct 
evidence in support of more recent reviews, meta-analysis and consensus guidelines [20, 21] as well 
as recent studies [22]. 
 
 
The higher all-cause mortality in patients not receiving RT after BCS is likely to reflect comorbidities 
not captured in the current study. Nevertheless, patients not receiving RT had a higher (7.2%) breast 
recurrence rate, confirming patient selection for RT could be improved. [23] 
Endocrine therapy was associated with a non-significant reduction in ipsilateral breast recurrence 
independent of RT, although the greatest effect was seen for the reduction of invasive further events 
in the absence of RT. In a contemporary analysis of the US retrospective National Cancer Data Base 
(70% of the US population), 36.5% of women (most commonly between 50 and 59 years of age) 
received adjuvant endocrine therapy for DCIS [24] compared with 12.2% in this UK-based study, and 
no-one in a cohort in the Netherlands [13], reflecting the inconsistent interpretation of evidence from 
trials examining the impact of endocrine therapy for DCIS on local recurrence, the associated 
toxicities and issues of adherence to adjuvant tamoxifen treatment. 
 
Significantly, neither the use of RT, endocrine therapy, nor type of surgery, appeared to influence 
breast cancer mortality, although women who developed invasive ipsilateral breast cancer had a 
poorer survival than those who had DCIS recurrence. Indeed, breast cancer mortality (0.46%) was a 
fifth of other cause mortality, in keeping with several retrospective studies. [3. 4, 13] 
 
11 
 
The increasing incidence of DCIS, likely to be sustained with the enhanced visualisation that digital 
mammography provides, now deployed in the UK NHS BSP, emphasises the potential for 
overtreatment of women diagnosed though breast screening. [1,25] Since digital mammography was 
not deployed during the time of data collection for this study, the impact of digital mammography 
and any influences on the data reported here remain uncertain. However, the present study findings 
do re-emphasise the issue of potential overtreatment of DCIS and the need to improve the selection 
of adjuvant therapy for women with DCIS. This requires a greater understanding of the underlying 
biology of DCIS, on reliable predictive and prognostic assessment, particularly to select women at risk 
of invasive breast cancer recurrence. Predictive models of ipsilateral breast recurrence after DCIS, 
and a more recent prognostic score for DCIS for RT benefit, require prospective validation if they are 
to be widely adopted. [26-30] Meanwhile, a major international initiative between the UK, 
Netherlands and the US, the PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment 
Now) study funded by Cancer Research UK and the Dutch Cancer Society seeks to define underlying 
molecular mechanisms in DCIS related to risk of progression and, together with diagnostic and clinical 
elements, construct risk models for the future management of patients. 
(http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-
challenge-award/funded-teams-wesseling) [30] Emulating studies in prostate, thyroid and renal 
neoplasia, active surveillance, rather than initial surgery, for carefully selected patients with low risk 
DCIS has been advocated and may avoid the potential sequelae of breast surgery. Indeed, 
prospective randomised trials of active surveillance versus conventional surgical care, e.g. the LOw 
RISk DCIS (LORIS) trial in the UK, COMET in the USA and LORD in mainland Europe [31-33] seek to 
identify a cohort of patients with sufficiently low risk to obviate the need for surgical excision. 
 
Conclusions 
This large prospective cohort study allows us to examine, in contemporary practice, the effects of 
present-day treatments, and the patient and pathological features that have previously been 
described in retrospective studies and randomised clinical trials. The reduction in recurrence rates 
seen with the use of RT and endocrine therapy has not, to date, yielded a survival benefit to patients, 
although other-cause mortality is five times greater than that attributable to breast cancer. Ipsilateral 
breast recurrence risk is, however, higher in patients treated by BCS without RT, particularly if the 
radial excision margin is narrow (<2mm). Women with recurrence as invasive disease have poorer 
survival than those with recurrent DCIS and further research targeting clinical, biological and imaging 
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biomarkers of risk of invasive recurrence after a diagnosis of screen-detected DCIS is indicated, to 
improve personalisation of therapy and outcomes. 
 
 
References 
 
1 Broders AC. Carcinoma in situ contrasted with benign penetrating epithelium. Journal of the 
American Medical Association. 1932 Nov 12;99(20):1670-4. 
 
2 Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer 
screening: an independent review. Lancet 2012; 380(9855):1778-86. 
 
3 Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of 
ductal carcinoma in situ. JAMA Oncology 2015;1(7):888–96. 
 
4 Sagara Y, Mallory MA, Wong S, et al. Survival benefit of breast surgery for low-grade ductal 
carcinoma in situ: a population-based cohort study. JAMA Surgery 2015;150(8):739-45. 
 
5 Duffy SW, Dibden A, Michalopoulos D, et al. Screen detection of ductal carcinoma in situ and 
subsequent incidence of invasive interval breast cancers: a retrospective population-based study. 
Lancet Oncol 2016;17(1):109–14.  
 
6 Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with 
locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 
2011;12(1):21–9. 
 
7 Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor 
recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl 
Cancer Inst 2011;103(6):478–88.  
 
8 Donker M, Litière S, Werutsky G et al. Breast-conserving treatment with or without 
radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from 
the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31(32):4054–9. 
 
9 http://www.sloaneproject.co.uk/Pathology.htm. (Accessed 15th May 2017) 
 
10 http://www.sloaneproject.co.uk/Radiology.htm. (Accessed 15th May 2017) 
 
11 Gale AG. PERFORMS: a self-assessment scheme for radiologists in breast screening. In 
Seminars in Breast Disease 2003 Sep 30 (Vol. 6, No. 3, pp. 148–152). WB Saunders. 
 
12 Clements K, Dodwell D, Lawrence G, et al. Radiotherapy after mastectomy for screen-detected 
ductal carcinoma in situ. Eur J Surg Oncol 2015;41(10):1406–10.  
 
13 Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. 
Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal 
carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 
women. Breast Cancer Res and Treat 2016;159(3):553–63. 
 
13 
 
14 Rakha EA, Bennett RL, Coleman D, Pinder SE, Ellis IO. Review of the national external 
quality assessment (EQA) scheme for breast pathology in the UK. J Clin Pathol. 2017;70(1):51–7 
 
15 Garg PK, Jakhetiya A, Pandey R, Chishi N, Pandey D. Adjuvant radiotherapy versus 
observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized 
controlled trials. Breast J. 2017 Aug 22. doi: 10.1111/tbj.12889. [Epub ahead of print] 
 
16 http://associationofbreastsurgery.org.uk/media/1418/abs-consensus-on-margin-width-in-breast-
conservation-surgery.pdf  
(accessed 29th May 2017) 
 
17 Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in 
situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 
2015;14;33(33):3938–44. 
 
18 Ekatah GE, Turnbull AK, Arthur LM, Thomas J, Dodds C, Dixon JM. Margin width and local 
recurrence after breast conserving surgery for ductal carcinoma in situ. Eur J Surg Oncol. 
2017;43(11):2029-2035 
 
19 Silverstein MJ, Lagios MD, Groshen S et al. The influence of margin width on local control of 
ductal carcinoma in situ of the breast. N Engl J Med 1999;340(19):1455–61. 
 
20 Toss MS, Pinder SE, Green AR, et al. Breast conservation in ductal carcinoma in situ (DCIS); 
what defines optimal margins? Histopathology 2017;70(5):681–692.  
 
21 Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology–American Society for 
Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for 
Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol 
2016;34(33):4040–6. 
 
22 Tadros AB, Smith BD, Shen Y, et al. Ductal Carcinoma In Situ and Margins <2 mm: 
Contemporary Outcomes With Breast Conservation. Ann Surg. 2017. doi: 
10.1097/SLA.0000000000002439. [Epub ahead of print] 
 
23 Smith GL. Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In 
Situ in the United States. J Clin Oncol 2016;34(11):1172–4. 
 
24 Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH. Adjuvant endocrine 
therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 
to 2012 in the National Cancer Data Base. Ann Surg Oncol 2015;22(10):3264–72. 
 
25 Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence 
after breast-conserving surgery or ductal carcinoma in situ. J Clin Oncol 2010;28(23):3762–9. 
 
26 Thornton H, Edwards A, Baum M. Women need better information about routine 
mammography. BMJ: British Medical Journal. 2003 Jul 12;327(7406):101. 
 
27 Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for 
predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after 
local excision. J Clin Oncol 2012;30(6):600–7. 
 
28 Smith GL, Smith BD, Haffty BG. Rationalization and regionalization of treatment for ductal 
carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2006;65(5):1397–403. 
14 
 
 
29 Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene Expression Assay and Benefit of 
Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ. J Natl Cancer Inst 
2017;109(4):1–8. 
 
30 Hwang ES, Thompson A. Editorial: What Can Molecular Diagnostics Add to Locoregional 
Treatment Recommendations for DCIS? J Natl Cancer Inst 2017;109(4). 
 
31 Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; 
the LORIS trial. Eur J Cancer 2015;51(16):2296–303. 
 
32 https://clinicaltrials.gov/ct2/show/NCT02926911 (accessed 30th October 2017) 
 
33 Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, 
international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for 
low risk ductal carcinoma in situ–the LORD study. Eur J Cancer 2015;51(12):1497–510. 
15 
 
 
Acknowledgements 1. Members of the Sloane Project Steering Group: 
Surgery 
Professor Alastair Thompson (Chair) 
Professor Adele Francis** 
Mr Mark Sibbering 
Mr Hugh Bishop (previous Chair) * 
Mr Robert Carpenter * 
Professor W D George * 
Mr Martin Lee * 
Mr Stewart Nicholson * 
Radiology 
Dr Hilary Dobson *  
Professor Andy Evans  
Dr Anthony Maxwell         
Dr Matthew Wallis  
Oncology 
Professor David Dodwell  
Dr Elinor Sawyer 
Dr Julian Adlard * 
Professor John Dewar * 
Dr Gillian Ross * 
Patient Representative 
Maggie Wilcox 
Pathology 
Professor Andrew Hanby  
Professor Sarah Pinder  
Professor Valerie Speirs  
Dr Jeremy Thomas  
Professor Ian Ellis * 
Professor Sunil Lakhani * 
Dr James Macartney * 
Molecular and Population Genetics 
16 
 
Professor Ian Tomlinson 
Bioinformatics 
Mrs Shan Cheung 
Dr Gill Lawrence 
Professor Graham Ball  
Management 
Mrs Karen Clements  
Mrs Bridget Hilton 
Mrs Olive Kearins  
Mrs Margot Wheaton *  
* Indicates former members of the steering group 
** deceased 
 
 
Appendix 
 
UK Breast Screening Units contributing to the Sloane Project: 
 
Avon North Derbyshire 
Barking, Havering, Redbridge & Brentwood North East Scotland 
Barnsley North Lancashire & South Cumbria 
Bedfordshire & Hertfordshire North London 
Bolton, Bury & Rochdale North Nottinghamshire 
Breast Test Wales – North* North Staffordshire 
Breast Test Wales – South East* North Yorkshire 
Breast Test Wales – South West* Northampton 
Cambridge & Huntingdon Nottingham 
Central & East London Oxfordshire 
Chelmsford & Colchester Pennine (Bradford) 
Chester Peterborough 
City, Sandwell & Walsall Portsmouth 
Cornwall Rotherham 
Crewe Sheffield 
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Doncaster Shropshire 
Dorset Somerset 
Dudley & Wolverhampton South Birmingham 
East Berkshire (Windsor) South Derbyshire 
East Cheshire & Stockport South Devon 
East Lancashire South East London & Queen Mary’s 
East Scotland South East Scotland 
East Sussex, Brighton & Hove South Essex 
Gateshead South Staffordshire 
Gloucestershire South West London (St George’s) 
Great Yarmouth & Waveney South West Scotland 
Greater Manchester Southampton & Salisbury 
Hereford & Worcester Surrey (Jarvis) 
Humberside Warrington 
Isle of Wight Warwickshire, Solihull & Coventry 
King’s Lynn West Berkshire 
Leeds & Wakefield West Devon & East Cornwall 
Leicestershire West Essex 
Liverpool West of London 
Maidstone West of Scotland 
Medway (Gillingham, Kent) West Suffolk 
Milton Keynes Western, Northern Ireland* 
Newcastle-Upon-Tyne Wiltshire 
Norfolk & Norwich Wirral 
North & Eastern Devon Wycombe 
North & Mid Hampshire  
North Cumbria  
* Unit data not included in these analyses 
Table 1: Radiotherapy (RT) use & pathological features after breast conservation surgery (BCS).  
 
 
  
Pathological feature 
No RT 
(% all cases) 
RT 
(% all cases) 
All cases 
(% with each feature type) 
Total number of cases  
5,497  
(55.3) 
4,396  
(44.2) 
9,938  
(100.0) 
Number of BCS cases 
2,616  
(37.3) 
4,363  
(62.3) 
7,007  
(70.5) 
Number of Mx cases 
2,881  
(98.3) 
33  
(1.1) 
2,931  
(29.5) 
Cytonuclear grade       
High  
770  
(19.2) 
3,240  
(80.6) 
4,020  
(57.4) 
Intermediate  
1,223  
(54.9) 
993  
(44.6) 
2,227  
(31.8) 
Low  
616  
(82.1) 
127  
(16.9) 
750  
(10.7) 
Unknown  
7  
(70.0) 
3  
(30.0) 
10 
 (0.1) 
Tumour size (mm)       
<10 
1,403  
(58.0) 
1,002  
(41.44) 
2,418  
(34.5) 
10 - <20 
808  
(33.2) 
1,619  
(66.5) 
2,434  
(34.7) 
20 - <30 
247  
(19.4) 
1,022  
(80.2) 
1,274  
(18.2) 
30 - <40 
85  
(16.7) 
423 
 (82.9) 
510  
(7.3) 
40 - <50 
33  
(15.8) 
176  
(84.2) 
209  
(3.0) 
50+ 
26  
(19.0) 
110  
(80.3) 
137  
(2.0) 
Unknown 
14  
(56.0) 
11  
(44.0) 
25  
(0.4) 
Microinvasion       
Yes 
70  
(19.0) 
298  
(81.0) 
368  
(5.3) 
No 
2,519  
(38.4) 
4,020  
(61.2) 
6,566  
(93.7) 
Unknown 
27  
(37.0) 
45  
(61.6) 
73  
(1.0) 
Comedo necrosis 
      
Yes 
1,006  
(24.3) 
3,116  
(75.3) 
4,137  
(59.0) 
No 
1,431  
(59.2) 
975  
(40.4) 
2,416  
(34.5) 
Unknown 
179  
(39.4) 
272  
(59.9) 
454  
(6.5) 
Radial margin (mm)    
0 
72  
(34.6) 
132  
(63.5) 
208  
(3.0) 
>0 to <1 
72  
(35.5) 
129  
(63.6) 
203  
(2.9) 
1 - <2 
183  
(35.0) 
337  
(64.4) 
523  
(7.5) 
2 - <5 
480  
(34.5) 
907  
(65.2) 
1,391 
 (19.9) 
5 - <10 
642  
(35.2) 
1,176  
(64.5) 
1,823  
(26.0) 
10+ 
1,055  
(41.4) 
1,486  
(58.3) 
2,547  
(36.4) 
Unknown 
112  
(35.9) 
196  
(62.8) 
312  
(4.5) 
Table
 
Figure 1: 9938 UK patients with screen-detected DCIS (2003-2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cases in Sloane Project database 
diagnosed from 01 April 2003 to 31 March 
2012 (n=12,838) 
On database excluding BTW and NI cases 
(n=12,403) 
Exclude Breast Test Wales 
(BTW) cases (n=395) and 
Northern Ireland (NI) cases (n= 
40).  Total excluded (n=435) 
Women/cases on database to be 
included in the analyses (9,938): 
Have had surgery; 
Do not have positive nodes; 
If bilateral, then primary with “worst 
prognosis” included; 
Have follow-up until 31/12/12 (further 
event, death, censor date with neither); 
Have 6 months or longer to recurrence, 
death or censor date; 
Do not have bilateral recurrences. 
On database with all three forms 
(n=11,051) 
Lesions on database recorded as DCIS, +/- 
ADH +/- LISN (n=10,198) 
Exclude cases without all 3 
forms Radiology, Treatment and 
Pathology.  Total excluded 
(n=1,352) 
Exclude cases with non-invasive 
disease but without DCIS 
(n=853) 
Exclude: 
No surgery cases (n=23); 
Case that had breast conserving 
surgery, then radiotherapy 
followed by mastectomy (n=1); 
Exclude node positive cases 
(n=14); 
Exclude the “best prognosis” 
lesion of the bilateral primaries 
(n=34); 
Exclude cases without follow-up 
until 31/12/12/ (n=170); 
Exclude cases with less than 6 
months to recurrence, death or 
censor date (n=9). 
Exclude bilateral recurrences 
(n=9) 
 
 
Figure
Figure 2: Radiotherapy (RT) and ipsilateral breast events. 
 
 Time from surgery of DCIS 
 0 2 4 6 8 
Number at risk 
RT low/int 1120 969 688 441 180 
RT high 3240 2763 1898 1098 420 
No RT low/int 1839 1587 1138 684 275 
No RT high 770 665 492 308 119 
Cumulative censoring 
RT low/int 0 133 380 602 850 
RT high 0 424 1172 1904 2553 
No RT low/int 0 199 569 965 1356 
No RT high 0 54 185 336 508 
 
 
  
Figure 3: Survival from the date of recurrence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Time from recurrence 
 0 2 4 6 8 
Number at risk 
Overall DCIS 226 149 73 27 3 
Overall Invasive 322 179 78 23 2 
Breast DCIS 226 149 73 27 3 
Breast Invasive 322 179 78 23 2 
Cumulative censoring 
Overall DCIS 0 75 150 195 219 
Overall Invasive 0 122 215 267 288 
Breast DCIS 0 77 153 199 223 
Breast Invasive 0 126 219 271 292 
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